[Treatment of XXXX --studies on clinical effects of @entity800 ].

@entity1 @entity7566 @entity6369 @entity4658 @entity5938 @entity19001 @entity11739 @entity800
Clinical effects of @entity800 ( @entity19001 ) in the treatment of @entity7566 was compared with those in the treatment of @entity7566 . @entity11739 was isolated from 33 (39.3%) out of 84 @entity1 with @entity6369 . @entity19001 was administered at a dose of 100 mg, three times daily (300 mg) for 14 days. In 31 (93.3%) of the 33 @entity1 with @entity7566 , @entity11739 was eliminated within 7 to 14 days after the start of administration, and, in two @entity1 , inclusion bodies decreased in number but persisted. The subjective and objective clinical symptoms, urethral discharge, polymorphonuclear leucocyte (PMNL) in smears, and @entity4658 in VB1 of the @entity1 with @entity7566 , disappeared in 56.0, 57.6, and 63.0% of the cases, and improved in 24.0, 30.0 and 29.6% respectively, whereas those of the @entity1 with @entity7566 , urethral discharge, PMNL, and @entity4658 in VB1 disappeared in 57.6, 56.9 and 32.9%, and improved in 26.9, 13.7 and 37.9%, respectively. There was no significant difference in the clinical effects of @entity19001 between cases of @entity7566 and those of @entity7566 . Marked improvement in clinical symptoms were observed between day 7 and day 14 of medication in cases of both chlamydial and @entity7566 . In nine out of 11 cases of @entity7566 where @entity19001 was ineffective, no Ureaplasma nor aerobes, nor @entity11739 , were isolated. In the remaining two cases where Ureaplasma and @entity5938 were isolated respectively, these two bacteria were eradicated after medication, but urethral discharge and PMNL remained unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)
